prostate cancer
Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer
June 3, 2019Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer
Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …
Insider Interview: Paving paths in prostate cancer
May 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer
Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …
NICE turns down Astellas’ Xtandi in prostate cancer
April 8, 2019Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer
February 18, 2019Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer
Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …
Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer
January 31, 2019Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer
Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …
Prostate cancer researchers win $2m to explore carboplatin therapy
November 7, 2018Research and Development Cancer, carboplatin therapy, prostate cancer
The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research …
FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer
July 16, 2018Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …
Sophiris halts cancer study after patient death
June 25, 2018Research and Development, Sales and Marketing Cancer, Sophiris, pharma, prostate cancer
Another clinical trial has been forced to a standstill as biotech firm Sophiris revealed that a patient death had prompted …
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer
June 5, 2018Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …
Keytruda offers significant hope in subset of prostate cancer
June 4, 2018Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, prostate cancer
Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at …
Sun Pharma drug combo scores FDA approval in advanced castration-resistant prostate cancer
May 23, 2018Research and Development, Sales and Marketing Cancer, Churchill Pharmaceuticals, FDA, Sun Pharma, US, Yonsa, pharma, prostate cancer
Sun Pharma is celebrating with the announcement that its CYP17 inhibitor Yonsa (abiraterone acetate) has been awarded FDA approval in …
May announces £75m prostate cancer boost
April 10, 2018Manufacturing and Production, Medical Communications Prostate Cancer UK, UK, biotech, drugs, pharma, pharmaceutical, prostate cancer
Prostate cancer has begun to receive more publicity in recent years in the UK, but not for the right reasons. …
Almost 40% of UK prostate cancer cases are diagnosed late, according to report
April 9, 2018Medical Communications, Research and Development, Sales and Marketing Cancer, UK, pharma, prostate cancer
A report conducted by charity Orchid has revealed a “worrying trend” in the treatment of prostate cancer, indicating that as …
NHS trials “world-leading” initiative to cut prostate cancer diagnoses to just days
March 5, 2018Research and Development, Sales and Marketing Cancer, MRI, NHS, pharma, prostate cancer
The NHS has revealed plans to cut the average diagnosis times for prostate cancer from six weeks to less than …
J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup
February 15, 2018Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer
Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
